Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Gamma-oryzanol: a novel promising supplement for diabetes mellitus

Universa Medicina · Vol. 44 No. 1 (2025) · hlm. 90–100

DOI
10.18051/UnivMed.2025.v44.90-100
ISSN
2407-2230, 1907-3062
Terbit
2025-03-09
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

The global prevalence of diabetes is rising at an alarming rate, with nearly 11% of adults currently affected. Projections estimate that by 2045, approximately 800 million individuals—1 in every 8 people—will have diabetes, representing a 46% increase in cases. Effective dietary management, however, offers the potential to delay or reduce diabetes-related complications. Gamma-oryzanol (γ-ORZ), a bioactive compound in brown rice (BR), has shown promising effects on type 2 diabetes mellitus (T2DM) and its complications, as evidenced by various scientific studies. Despite its potential, γ-ORZ's mechanisms of action remain underexplored, and BR consumption is less prevalent compared to white rice (WR). This review aimed to examine the effects of γ-ORZ on diabetes, promoting further research and encouraging the adoption of BR in dietary practices. Relevant studies were identified through a systematic search of PubMed, ScienceDirect, and Google Scholar for articles published between January 2013 and December 2023 using the keywords “(Gamma-oryzanol OR γ-oryzanol OR γ-ORZ) AND (Diabetes Mellitus OR Type-2 diabetes mellitus OR T2DM OR Hyperglycemia OR Insulin Resistance).” From an initial pool of 1,912 articles, 15 studies meeting the inclusion criteria were reviewed. Findings revealed that γ-ORZ exhibits antihyperglycemic, antidyslipidemic, anti-inflammatory, and antioxidant properties. It mitigates β-cell dysfunction, improves adipocyte function, enhances insulin secretion and sensitivity, and alleviates diabetic cardiomyopathy. This review underscores γ-ORZ's therapeutic potential in managing diabetes and its complications, while highlighting the need for more robust studies to validate its efficacy and compare it with standard treatments.

Kata kunci

Jaringan kolaborasi para penulis

25 penulis · 115 tautan kepenulisan bersama · 50 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universiti Sains Malaysia
  • Universitas Trisakti
  • Universitas Negeri Padang
  • Al-Qasim Green University
  • Federal University Dutsin-Ma
  • Shanghai University of Sport
  • Democritus University of Thrace
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Abubakar IbrahimAfiliasi tidak diketahui1
Yuni AstutiUniversitas Negeri Padang1
Sameer Badri Al-MhannaAl-Qasim Green University1
Karrar Jasim HamzahAl-Qasim Green University1
EldawatyUniversitas Negeri Padang1
EriantiUniversitas Negeri Padang1
Haripah LawanisUniversitas Negeri Padang1
Ain’ Sabreena Mohd NohUniversiti Sains Malaysia1
Marilyn GilyanaAfiliasi tidak diketahui1
Mingyue YinShanghai University of Sport1
Alexios BatrakoulisDemocritus University of Thrace1
Nany HairunisaUniversitas Trisakti1
Husnun AmaliaUniversitas Trisakti1
Yasmine MashabiUniversitas Trisakti1
Ade Dwi LestariUniversitas Trisakti1
Nabila AngelicaUniversitas Trisakti1
Muthia Ariana PutriUniversitas Trisakti1
Salma KhairunnisaUniversitas Trisakti1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 10 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Gamma-oryzanol: a novel promising supplement  for diabetes mellitus</dc:title>
	<dc:creator xml:lang="en">Radda, Mustapha Ismail </dc:creator>
	<dc:creator xml:lang="en">Omar, Norsuhana </dc:creator>
	<dc:creator xml:lang="en">Ahmad, Rozaziana  </dc:creator>
	<dc:creator xml:lang="en">Jalil, Rohana Abdul</dc:creator>
	<dc:creator xml:lang="en">Ishak, Wan Rosli Wan   </dc:creator>
	<dc:creator xml:lang="en">Zin, Anani Aila Mat </dc:creator>
	<dc:creator xml:lang="en">Romli, Aminah Che </dc:creator>
	<dc:subject xml:lang="en">Diabetes</dc:subject>
	<dc:subject xml:lang="en">diabetic complications</dc:subject>
	<dc:subject xml:lang="en">gamma-oryzanol</dc:subject>
	<dc:subject xml:lang="en">insulin secretion</dc:subject>
	<dc:subject xml:lang="en">insulin resistance</dc:subject>
	<dc:description xml:lang="en">The global prevalence of diabetes is rising at an alarming rate, with nearly 11% of adults currently affected. Projections estimate that by 2045, approximately 800 million individuals—1 in every 8 people—will have diabetes, representing a 46% increase in cases. Effective dietary management, however, offers the potential to delay or reduce diabetes-related complications. Gamma-oryzanol (γ-ORZ), a bioactive compound in brown rice (BR), has shown promising effects on type 2 diabetes mellitus (T2DM) and its complications, as evidenced by various scientific studies. Despite its potential, γ-ORZ's mechanisms of action remain underexplored, and BR consumption is less prevalent compared to white rice (WR). This review aimed to examine the effects of γ-ORZ on diabetes, promoting further research and encouraging the adoption of BR in dietary practices. Relevant studies were identified through a systematic search of PubMed, ScienceDirect, and Google Scholar for articles published between January 2013 and December 2023 using the keywords “(Gamma-oryzanol OR γ-oryzanol OR γ-ORZ) AND (Diabetes Mellitus OR Type-2 diabetes mellitus OR T2DM OR Hyperglycemia OR Insulin Resistance).” From an initial pool of 1,912 articles, 15 studies meeting the inclusion criteria were reviewed. Findings revealed that γ-ORZ exhibits antihyperglycemic, antidyslipidemic, anti-inflammatory, and antioxidant properties. It mitigates β-cell dysfunction, improves adipocyte function, enhances insulin secretion and sensitivity, and alleviates diabetic cardiomyopathy. This review underscores γ-ORZ's therapeutic potential in managing diabetes and its complications, while highlighting the need for more robust studies to validate its efficacy and compare it with standard treatments.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2025-03-09</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1636</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2025.v44.90-100</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 44 No. 1 (2025); 90-100</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2025.v44.i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1636/814</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2025 Mustapha Ismail  Radda, Norsuhana  Omar, Rozaziana   Ahmad, Rohana Abdul Jalil, Wan Rosli Wan    Ishak, Anani Aila Mat  Zin, Aminah Che  Romli</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>